Atypical Antidepressants: Pharmacology Made Easy & Clinically Relevant
Atypical antidepressants offer unique pharmacologic profiles that give them advantages over other classes of antidepressants, including even smoking cessation & insomnia. Learning the why helps us master the how in using these medications.
To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this This Is Why with Dr. Busti pharmacology review, Dr. Busti explores the atypical antidepressants—a diverse group of agents that work beyond traditional SSRI and SNRI mechanisms. This class includes bupropion, mirtazapine, trazodone, vilazodone, and vortioxetine, each offering unique neurotransmitter targets, side effect profiles, and clinical roles. The goal = Pharmacology Made Easy
Learn why these agents are valuable not only for major depressive disorder but also as adjuncts to SSRI therapy, when managing patients with overlapping anxiety, sleep, appetite, or sexual side effect considerations. Dr. Busti walks through how each drug modulates neurotransmission in the central nervous system, the key pharmacokinetic and pharmacodynamic principles behind their activity, and how to use their differences to tailor treatment effectively.
This episode also covers metabolic pathways (CYP2D6, CYP3A4, CYP2C19), genetic polymorphisms, clinical contraindications, and side effect management—connecting the why behind drug selection to the how of real-world patient care.
Chapter Table of Contents
00:00 Introduction to Atypical Antidepressants & Pharmacology Review
01:03 Why Atypical Antidepressants Matter: MDD Monotherapy & SSRI Augmentation
01:50 Drug Lineup & Common Indications: Bupropion, Mirtazapine, Trazodone, Vilazodone, Vortioxetine
04:43 Neurotransmitter & Receptor Targets: Dopamine, Norepinephrine, Serotonin & Other Receptors
06:19 Mechanism of Action in the CNS: Synaptic Transmission & Antidepressant Pathways
17:07 Bupropion & Mirtazapine: NE/DA Modulation, Activation, Weight Change & Seizure Risk
18:53 Trazodone, Vilazodone & Vortioxetine: Sedation, 5-HT1A Partial Agonism & Sexual Side Effects
22:11 Pharmacokinetics & CYP Interactions: CYP2D6, CYP3A4, St John’s Wort & Pharmacogenomics
28:06 Safety, Boxed Warnings, Seizure Risk & Clinical Monitoring with Atypical Antidepressants
#atypicalantidepressants #pharmacology #PsychiatryPharmacology #medicaleducation #Pharmacologymadeeasy
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
